MedTrace Logo

HBPL Study of the Impact of the NK1 Antagonist Aprepitant

NCT01176591 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2020-07-15

Study results available
· View outcomes & findings →

Summary

The proposed research will focus on investigating the determinants and consequences of CAD via measurement of physiological, behavioral and subjective effects of physiologic and psychologic stress cues in CAD volunteers in the laboratory, and through examination of the effects of the effects of Aprepitant, an NK1 antagonist, on the above effects. This study will examine the effects of the above stress cues on cocaine and alcohol craving under acute Aprepitant dosing, and under placebo conditions. The study is a within-subjects crossover design using 24 subjects.

Conditions

  • Cocaine Dependence
  • Alcohol Dependence

Interventions

DRUG

Placebo session 1, Aprepitant session 2

placebo in session 1, Aprepitant 80 mg in session 2, oral administration.

DRUG

Placebo session 1, Placebo session 2

Placebo, one per session, oral administration

Sponsors & Collaborators

Principal Investigators

  • Kyle M Kampman, MD · Perelman School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2013-09-30
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01176591 on ClinicalTrials.gov